Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

US FDA grants priority review for Keytruda & Keytruda Qlex, each in combination with Padcev, for certain patients with muscle-invasive bladder cancer: Rahway, New Jersey Friday, O ...

Merck (MRK) stock is in focus as the company's Keytruda versions win FDA priority review for an expanded indication in ...

The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Merck (MRK) announced that the U.S. FDA has granted priority review for two supplemental Biologics License Applications for Keytruda and Keytruda ...

Analysis - The number of people receiving treatment for cancer has risen dramatically in the last decade in many African countries. For example, 10 years ago in Ethiopia and Kenya, cancer care was ...

MADRID -- The high-dose inactivated influenza vaccine may reduce older people's risk of hospitalization for flu or pneumonia more than a standard-dose shot, according to two large open-label, ...

The number of people receiving treatment for cancer has risen dramatically in the last decade in many African countries. For ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...

Pfizer, Merck, AstraZeneca and Bristol Myers Squibb were among the many biopharmas showing off novel cancer modalities at ...